Forrer F - Search Results

1

Up-regulation of somatostatin receptor density on rat CA20948 tumors escaped from low dose [177Lu-DOTA0,Tyr3]octreotate therapy.

Melis M, Forrer F, Capello A, Bijster M, Bernard BF, Reubi JC, Krenning EP, De Jong M. Melis M, et al. Among authors: forrer f. Q J Nucl Med Mol Imaging. 2007 Dec;51(4):324-33. Q J Nucl Med Mol Imaging. 2007. PMID: 17923824 Free article.

2

A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours.

Forrer F, Uusijärvi H, Waldherr C, Cremonesi M, Bernhardt P, Mueller-Brand J, Maecke HR. Forrer F, et al. Eur J Nucl Med Mol Imaging. 2004 Sep;31(9):1257-62. doi: 10.1007/s00259-004-1553-6. Epub 2004 Jun 10. Eur J Nucl Med Mol Imaging. 2004. PMID: 15197500 Clinical Trial.

3

Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC.

Forrer F, Uusijärvi H, Storch D, Maecke HR, Mueller-Brand J. Forrer F, et al. J Nucl Med. 2005 Aug;46(8):1310-6. J Nucl Med. 2005. PMID: 16085587 Free article. Clinical Trial.

4

In vivo radionuclide uptake quantification using a multi-pinhole SPECT system to predict renal function in small animals.

Forrer F, Valkema R, Bernard B, Schramm NU, Hoppin JW, Rolleman E, Krenning EP, de Jong M. Forrer F, et al. Eur J Nucl Med Mol Imaging. 2006 Oct;33(10):1214-7. doi: 10.1007/s00259-006-0178-3. Epub 2006 Jul 11. Eur J Nucl Med Mol Imaging. 2006. PMID: 16832630

5

Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate.

Rolleman EJ, Forrer F, Bernard B, Bijster M, Vermeij M, Valkema R, Krenning EP, de Jong M. Rolleman EJ, et al. Among authors: forrer f. Eur J Nucl Med Mol Imaging. 2007 May;34(5):763-771. doi: 10.1007/s00259-006-0291-3. Epub 2006 Dec 5. Eur J Nucl Med Mol Imaging. 2007. PMID: 17146655

6

Anaphylactoid reaction from amifostine.

Rolleman EJ, Forrer F, Deckers J, de Groot H, Valkema R, de Jong M, Krenning EP. Rolleman EJ, et al. Among authors: forrer f. Radiother Oncol. 2007 Jan;82(1):110-1; author reply 111. doi: 10.1016/j.radonc.2006.10.024. Epub 2006 Dec 20. Radiother Oncol. 2007. PMID: 17184864 No abstract available.

7

Neuroendocrine tumors. Peptide receptor radionuclide therapy.

Forrer F, Valkema R, Kwekkeboom DJ, de Jong M, Krenning EP. Forrer F, et al. Best Pract Res Clin Endocrinol Metab. 2007 Mar;21(1):111-29. doi: 10.1016/j.beem.2007.01.007. Best Pract Res Clin Endocrinol Metab. 2007. PMID: 17382268 Review.

8

Is it possible to predict renal function in small animals using a multi-pinhole SPECT system.

Forrer F, Rolleman E, Schramm N, Krenning EP, de Jong M. Forrer F, et al. Eur J Nucl Med Mol Imaging. 2007 Jul;34(7):1127-8. doi: 10.1007/s00259-007-0445-y. Eur J Nucl Med Mol Imaging. 2007. PMID: 17497105 Free PMC article. No abstract available.

9

From outside to inside? Dose-dependent renal tubular damage after high-dose peptide receptor radionuclide therapy in rats measured with in vivo (99m)Tc-DMSA-SPECT and molecular imaging.

Forrer F, Rolleman E, Bijster M, Melis M, Bernard B, Krenning EP, de Jong M. Forrer F, et al. Cancer Biother Radiopharm. 2007 Feb;22(1):40-9. doi: 10.1089/cbr.2006.353. Cancer Biother Radiopharm. 2007. PMID: 17627412

10

Diagnostic versus therapeutic doses of [(177)Lu-DOTA-Tyr(3)]-octreotate: uptake and dosimetry in somatostatin receptor-positive tumors and normal organs.

Müller C, Forrer F, Bernard BF, Melis M, Konijnenberg M, Krenning EP, de Jong M. Müller C, et al. Among authors: forrer f. Cancer Biother Radiopharm. 2007 Feb;22(1):151-9. doi: 10.1089/cbr.2007.309. Cancer Biother Radiopharm. 2007. PMID: 17627424

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

64 results

Search Page